Showing results (2581-2590 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 1, 2021
A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphomaMonica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, et al.
Investigational New Drugs|February 3, 2021
Autophagy promotes oncolysis of an adenovirus expressing apoptin in human bladder cancer modelsChao Shang, Yi-Long Zhu, Yi-Quan Li, et al.
Investigational New Drugs|November 4, 2021
A phase 1 study of pegylated recombinant arginase (PEG-BCT-100) in combination with systemic chemotherapy (capecitabine and oxaliplatin)[PACOX] in advanced hepatocellular carcinoma patientsThomas Yau, Paul N M Cheng, Joanne Chiu, et al.
Investigational New Drugs|January 1, 1987
Treatment of chronic myelogenous leukemia with recombinant interferon alfa-2bN Niederle, O Kloke, D May, et al.
Investigational New Drugs|November 29, 2021
A phase 1 study to assess the safety, pharmacokinetics, and anti-tumor activity of the androgen receptor n-terminal domain inhibitor epi-506 in patients with metastatic castration-resistant prostate cancerCorinne Maurice-Dror, Ronan Le Moigne, Ulka Vaishampayan, et al.
Investigational New Drugs|December 1, 1987
Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)C P Steuber, V J Land, C I Civin, et al.
Investigational New Drugs|December 1, 1987
Mitoxantrone in the treatment of acute leukemiaD A Vorobiof, G Falkson, M A Coccia-Portugal, et al.
Investigational New Drugs|October 26, 2022
Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemiaYanfeng Liu, Yan Jia, Yi Liu, et al.
Investigational New Drugs|September 5, 2022
Comparison of dual mTORC1/2 inhibitor AZD8055 and mTORC1 inhibitor rapamycin on the metabolism of breast cancer cells using proton nuclear magnetic resonance spectroscopy metabolomicsZhitao Ni, Shaolin Xu, Zheng Yu, et al.
Investigational New Drugs|October 1, 2021
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung CancerAdelina Plangger, Barbara Rath, Maximilian Hochmair, et al.
Pageof 372